glp-1 for metabolic syndrome Resmetirom and agonists MASH: complementary rather than exclusive GLP-1 Therapy Part 1: Setting
Description

Ibil Bykcokun N, Gle G, Cam Etz B, Ozlk K

Clinical Evidence Several clinical trials and studies underscore the cardiovascular benefits of GLP-1 receptor agonists: SUSTAIN-6 Trial : This pivotal trial demonstrated a significant reduction in major adverse cardiovascular events (MACE) among patients treated with GLP-1 compared to placebo

The mechanism behind this effect has been investigated using direct reactive quenching and has been linked to the antioxidant activity of DPP4 inhibitors

Management of gallstones and gallbladder disease in patients undergoing gastric bypass

The research community is still building the full picture
